PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28034764-4 2018 The concept is based on the fact that vitamin D3 activates via its metabolite 1alpha,25-dihydroxyvitamin D3 the transcription factor vitamin D receptor and thus has a direct effect on the epigenome and transcriptome of many human tissues and cell types. Cholecalciferol 38-48 vitamin D receptor Homo sapiens 133-151 29844206-4 2018 Activation of Vdr signaling by the vitamin D3 agonist calcitriol increased the outgrowth of EryD colonies from fetal liver and adult bone marrow, maintained progenitor potential, and delayed erythroid maturation, as revealed by clonogenic assays, suspension culture, cell surface phenotype, and gene expression analyses. Cholecalciferol 35-45 vitamin D receptor Homo sapiens 14-17 29726119-9 2018 Vitamin D3 levels appeared to be modulated by genetic variation in CYP24A1 and VDR genes. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 79-82 29875733-1 2018 The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] is the exclusive high-affinity ligand of the vitamin D receptor (VDR), a transcription factor with direct effects on gene expression. Cholecalciferol 4-14 vitamin D receptor Homo sapiens 115-133 29875733-1 2018 The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] is the exclusive high-affinity ligand of the vitamin D receptor (VDR), a transcription factor with direct effects on gene expression. Cholecalciferol 4-14 vitamin D receptor Homo sapiens 135-138 29165303-2 2017 However, VDR activation leads to the expression of CYP24A1, a hydroxylase that can inactivate vitamin D3 metabolites. Cholecalciferol 94-104 vitamin D receptor Homo sapiens 9-12 28315703-1 2017 The molecular endocrinology of vitamin D is based on the facts that i) its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) is the high affinity ligand of the nuclear receptor vitamin D receptor (VDR) and ii) the transcription factor VDR is the unique target of 1,25(OH)2D3 in the nucleus. Cholecalciferol 113-115 vitamin D receptor Homo sapiens 202-205 28315703-1 2017 The molecular endocrinology of vitamin D is based on the facts that i) its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) is the high affinity ligand of the nuclear receptor vitamin D receptor (VDR) and ii) the transcription factor VDR is the unique target of 1,25(OH)2D3 in the nucleus. Cholecalciferol 113-115 vitamin D receptor Homo sapiens 240-243 28891930-3 2017 The active metabolite of vitamin D3 has an immunoregulatory role mediated by binding to the vitamin D receptor (VDR) in monocyte, macrophages, and lymphocytes. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 92-110 28891930-3 2017 The active metabolite of vitamin D3 has an immunoregulatory role mediated by binding to the vitamin D receptor (VDR) in monocyte, macrophages, and lymphocytes. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 112-115 28891930-9 2017 CONCLUSION: Genetic polymorphism in two SNP in VDR may be correlated with development of ASD symptoms by influencing functionality of vitamin D3 metabolism, while vitamin D3 levels were not significantly different between ASD and non-ASD children. Cholecalciferol 134-144 vitamin D receptor Homo sapiens 47-50 28692301-7 2017 Adjunctive vitamin D3 accelerated sputum culture conversion in patients with one or more minor alleles for SNPs in genes encoding the vitamin D receptor (rs4334089, rs11568820) and 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1: rs4646536) (adjusted hazard ratio >= 1.47; P for interaction <= 0.02). Cholecalciferol 11-21 vitamin D receptor Homo sapiens 134-152 28662432-7 2017 RESULTS: Low vitamin D3 levels were accompanied with decreased expression of cathelicidin and VDR in PKDL-BT patients. Cholecalciferol 13-23 vitamin D receptor Homo sapiens 94-97 28938596-0 2017 Vitamin D3 induces vitamin D receptor and HDAC11 binding to relieve the promoter of the tight junction proteins. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 19-37 28592257-2 2017 Ointment containing 1,25-dihydroxy-22-oxavitamin D3 (maxacalcitol), a noncalcemic analog of the active form of vitamin D3, is applied for the treatment of hyperkeratotic cutaneous conditions such as psoriasis and ichtyosis because it suppresses the proliferation and promotes the differentiation of keratinocytes through interaction with the vitamin D receptor. Cholecalciferol 41-51 vitamin D receptor Homo sapiens 342-360 28665937-6 2017 We observed a reduction in the expression of TLR7, TLR9, INF-gamma and CYP24a1 and an increase in VDR and CYP27b1 expression in patients which were supplemented with cholecalciferol, whereas no differences were found in the placebo group. Cholecalciferol 166-181 vitamin D receptor Homo sapiens 98-101 27978548-15 2017 Conclusions and Relevance: Our findings suggest that benefits from vitamin D3 supplementation for the prevention of advanced colorectal adenomas may vary according to vitamin D receptor genotype. Cholecalciferol 67-77 vitamin D receptor Homo sapiens 167-185 27454349-1 2016 INTRODUCTION: Vitamin D3 activates via its hormonal form 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the transcription factor vitamin D receptor (VDR). Cholecalciferol 14-24 vitamin D receptor Homo sapiens 132-150 28001444-4 2017 We demonstrated VDR protein expression in primary plasmablastic tumor cells and confirmed in cell lines expression of both VDR and the metabolic enzyme CYP27B1, which catalyzes active vitamin D3 production. Cholecalciferol 184-194 vitamin D receptor Homo sapiens 123-126 28001444-7 2017 Furthermore, a VDR polymorphism, FOK1, was associated with greater vitamin D3-dependent growth inhibition. Cholecalciferol 67-77 vitamin D receptor Homo sapiens 15-18 29074830-3 2017 An active form of vitamin D3, 1alpha,25(OH)2D3, binds to vitamin D nuclear receptor(VDR, vitamin D receptor), and regulates expression of specific target genes. Cholecalciferol 18-28 vitamin D receptor Homo sapiens 84-87 29074830-3 2017 An active form of vitamin D3, 1alpha,25(OH)2D3, binds to vitamin D nuclear receptor(VDR, vitamin D receptor), and regulates expression of specific target genes. Cholecalciferol 18-28 vitamin D receptor Homo sapiens 89-107 27942020-12 2016 We hypothesize that the vitamin D receptor-lithocholic acid partnership evolved as a by-product of natural selection on the ligand-receptor partnership between the vitamin D receptor and the native VDR ligand: 1alpha,25-dihydroxyvitamin D3, the biologically active metabolite of vitamin D3. Cholecalciferol 229-239 vitamin D receptor Homo sapiens 24-42 27942020-12 2016 We hypothesize that the vitamin D receptor-lithocholic acid partnership evolved as a by-product of natural selection on the ligand-receptor partnership between the vitamin D receptor and the native VDR ligand: 1alpha,25-dihydroxyvitamin D3, the biologically active metabolite of vitamin D3. Cholecalciferol 229-239 vitamin D receptor Homo sapiens 164-182 27942020-12 2016 We hypothesize that the vitamin D receptor-lithocholic acid partnership evolved as a by-product of natural selection on the ligand-receptor partnership between the vitamin D receptor and the native VDR ligand: 1alpha,25-dihydroxyvitamin D3, the biologically active metabolite of vitamin D3. Cholecalciferol 229-239 vitamin D receptor Homo sapiens 198-201 27161894-9 2016 In monocytes, while CYP27B1 expression and VDR expression increased in the cholecalciferol group (p < 0.05), CYP27B1 expression did not change, and VDR expression decreased in the control group (p < 0.05). Cholecalciferol 75-90 vitamin D receptor Homo sapiens 43-46 27897272-1 2016 Calcitriol, the active form of vitamin D3, can regulate the gene expression through the binding to the nuclear receptor VDR, but it can also display nongenomic actions, acting through a membrane-associated receptor, which has been discovered as the disulfide isomerase ERp57. Cholecalciferol 31-41 vitamin D receptor Homo sapiens 120-123 27454349-1 2016 INTRODUCTION: Vitamin D3 activates via its hormonal form 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3), the transcription factor vitamin D receptor (VDR). Cholecalciferol 14-24 vitamin D receptor Homo sapiens 152-155 27107558-0 2016 Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 78-96 27107558-12 2016 In conclusion, we have shown that vitamin D3 transactivates the SLC30A10 gene in a VDR-dependent manner, resulting in increased ZnT10 protein expression. Cholecalciferol 34-44 vitamin D receptor Homo sapiens 83-86 27345382-10 2016 However, when the genetic variants of the VDR gene were analyzed after adjusting for the serum 25-OH vitamin D3 level, the TaqI and BsmI minor allele increased the risk of PD. Cholecalciferol 101-111 vitamin D receptor Homo sapiens 42-45 27595605-1 2016 BACKGROUND: The vitamin D receptor (VDR) mediates the immunological function of vitamin D3, which activates macrophages, and vitamin D deficiency has been linked to tuberculosis risk. Cholecalciferol 80-90 vitamin D receptor Homo sapiens 16-34 27595605-1 2016 BACKGROUND: The vitamin D receptor (VDR) mediates the immunological function of vitamin D3, which activates macrophages, and vitamin D deficiency has been linked to tuberculosis risk. Cholecalciferol 80-90 vitamin D receptor Homo sapiens 36-39 27500498-1 2016 The active metabolite of vitamin D3 , 1alpha,25-dihydroxyvitamin D3 , acts as a ligand for the vitamin D receptor (VDR) and activates VDR-mediated gene expression. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 95-113 27500498-1 2016 The active metabolite of vitamin D3 , 1alpha,25-dihydroxyvitamin D3 , acts as a ligand for the vitamin D receptor (VDR) and activates VDR-mediated gene expression. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 115-118 27500498-1 2016 The active metabolite of vitamin D3 , 1alpha,25-dihydroxyvitamin D3 , acts as a ligand for the vitamin D receptor (VDR) and activates VDR-mediated gene expression. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 134-137 27500498-2 2016 Recently, we characterized 1alpha,25-dihydroxyvitamin D3 -26,23-lactams (DLAMs), which mimic vitamin D3 metabolites, as noncalcemic VDR ligands that barely activate the receptor. Cholecalciferol 46-56 vitamin D receptor Homo sapiens 132-135 27369077-2 2016 The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores. Cholecalciferol 35-45 vitamin D receptor Homo sapiens 4-22 27369077-2 2016 The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores. Cholecalciferol 35-45 vitamin D receptor Homo sapiens 24-27 27369077-2 2016 The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores. Cholecalciferol 97-107 vitamin D receptor Homo sapiens 4-22 27369077-2 2016 The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores. Cholecalciferol 97-107 vitamin D receptor Homo sapiens 24-27 27369077-2 2016 The vitamin D receptor (VDR) binds vitamin D3 and a second receptor, importin-4, imports the VDR-vitamin D3 complex into the nucleus via nuclear pores. Cholecalciferol 97-107 vitamin D receptor Homo sapiens 93-96 27369077-8 2016 The PoreWalker algorithm indicates that, of the 427 residues in each VDR monomer, 91 line the largest channel, including two vitamin D3 binding sites and residues from both the TM helix and "half-helix". Cholecalciferol 125-135 vitamin D receptor Homo sapiens 69-72 27369077-10 2016 Programmed changes in bound cholesterol may regulate both membrane Ca(2+) response systems and vitamin D3 uptake as well as receptor internalization by the endomembrane system culminating in uptake of the vitamin D3-VDR-importin-4 complex into the nucleus. Cholecalciferol 205-215 vitamin D receptor Homo sapiens 216-219 27154546-1 2016 The active form of vitamin D3 (1alpha,25(OH)2D3, also known as calcitriol) controls the expression of target genes via the vitamin D receptor (VDR). Cholecalciferol 19-29 vitamin D receptor Homo sapiens 123-141 27154546-1 2016 The active form of vitamin D3 (1alpha,25(OH)2D3, also known as calcitriol) controls the expression of target genes via the vitamin D receptor (VDR). Cholecalciferol 19-29 vitamin D receptor Homo sapiens 143-146 26694996-7 2016 Vitamin D3 was protective against vitamin D deficiency-induced cholesterol increase by maintaining the transcriptional activity of VDR and Insig-2 expression. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 131-134 27091127-7 2016 CONCLUSIONS: We found that however all normal and malignant germ-line derived cells express functional VDR, Vitamin D3 differently affects their proliferation and migration. Cholecalciferol 108-118 vitamin D receptor Homo sapiens 103-106 27058533-1 2016 Ultraviolet (UV) radiation is involved in almost all skin cancer cases, but on the other hand, it stimulates the production of pre-vitamin D3, whose active metabolite, 1,25-dihydroxyvitamin D3 (1,25VD3), plays important physiological functions on binding with its receptor (vitamin D receptor, VDR). Cholecalciferol 131-141 vitamin D receptor Homo sapiens 294-297 26943970-7 2016 In this study, activated microglia increased the expression of the vitamin D receptor and Cyp27b1, which encodes the enzyme for converting vitamin D3 into its active form, thereby enhancing their responsiveness to vitamin D3. Cholecalciferol 139-149 vitamin D receptor Homo sapiens 67-85 26943970-7 2016 In this study, activated microglia increased the expression of the vitamin D receptor and Cyp27b1, which encodes the enzyme for converting vitamin D3 into its active form, thereby enhancing their responsiveness to vitamin D3. Cholecalciferol 214-224 vitamin D receptor Homo sapiens 67-85 26827949-1 2016 The vitamin D nuclear receptor (VDR) and its natural ligand, 1alpha,25-dihydroxyvitamin D3 hormone (1,25(OH)2D3, or calcitriol), classically regulate mineral homeostasis and metabolism but also much broader range of biological functions, such as cell growth, differentiation, antiproliferation, apoptosis, adaptive/innate immune responses. Cholecalciferol 88-90 vitamin D receptor Homo sapiens 4-30 26827960-1 2016 The Arg274 residue of the ligand binding domain of human vitamin D receptor (hVDR) is important for 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) binding as a specific ligand through forming a hydrogen bond with the 1alpha-OH group of the active vitamin D3, 1alpha,25(OH)2D3. Cholecalciferol 119-129 vitamin D receptor Homo sapiens 57-75 26827960-1 2016 The Arg274 residue of the ligand binding domain of human vitamin D receptor (hVDR) is important for 1alpha,25-dihydroxyvitamin D3 (1alpha,25(OH)2D3) binding as a specific ligand through forming a hydrogen bond with the 1alpha-OH group of the active vitamin D3, 1alpha,25(OH)2D3. Cholecalciferol 119-129 vitamin D receptor Homo sapiens 77-81 26977043-1 2016 BACKGROUND: Vitamin D3 can be metabolized in the skin to 25(OH)D and 1,25(OH)2D because the skin expresses vitamin D-25-hydroxylase, 25(OH)D-1-alpha-hydroxylase, and the vitamin D receptor. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 170-188 26902087-2 2016 The VDR binds to active vitamin D3 metabolites, which stimulates downstream transduction signaling involved in various physiological activities such as calcium homeostasis, bone mineralization, and cell differentiation. Cholecalciferol 24-34 vitamin D receptor Homo sapiens 4-7 26827949-1 2016 The vitamin D nuclear receptor (VDR) and its natural ligand, 1alpha,25-dihydroxyvitamin D3 hormone (1,25(OH)2D3, or calcitriol), classically regulate mineral homeostasis and metabolism but also much broader range of biological functions, such as cell growth, differentiation, antiproliferation, apoptosis, adaptive/innate immune responses. Cholecalciferol 88-90 vitamin D receptor Homo sapiens 32-35 26184408-3 2015 The discovery that almost all tissues and cells in the body express the VDR and that several tissues possess the enzymatic capability to convert 25-hydroxyvitamin D (25(OH)-D3; cholecalciferol) to the active form, suggests that vitamin D fulfills various extra-osseous functions (Bouillon et al., Endocr Rev 29(6):726-776, 2008; Holick, N Engl J Med 357(3):266-281, 2007). Cholecalciferol 177-192 vitamin D receptor Homo sapiens 72-75 26904855-3 2015 Vitamin D metabolic enzymes synthesize and degrade active vitamin D3 and its metabolic intermediates, and active vitamin D3 exerts its biological effects through binding to vitamin D receptor (VDR). Cholecalciferol 58-68 vitamin D receptor Homo sapiens 193-196 26904855-3 2015 Vitamin D metabolic enzymes synthesize and degrade active vitamin D3 and its metabolic intermediates, and active vitamin D3 exerts its biological effects through binding to vitamin D receptor (VDR). Cholecalciferol 113-123 vitamin D receptor Homo sapiens 173-191 26904855-3 2015 Vitamin D metabolic enzymes synthesize and degrade active vitamin D3 and its metabolic intermediates, and active vitamin D3 exerts its biological effects through binding to vitamin D receptor (VDR). Cholecalciferol 113-123 vitamin D receptor Homo sapiens 193-196 26904855-4 2015 VDR and vitamin D metabolic enzymes expressed in male reproductive system, it suggest that vitamin D3 plays a pivotal role in male reproductive biology. Cholecalciferol 91-101 vitamin D receptor Homo sapiens 0-3 25931412-1 2015 Several compounds are produced along the complex pathways of vitamin D3 metabolism, and synthetic analogs have been generated to improve kinetics and/or vitamin D receptor activation. Cholecalciferol 61-71 vitamin D receptor Homo sapiens 153-171 26501255-1 2015 Vitamin D3 shows tumoristatic and anticancer effects by acting through the vitamin D receptor (VDR), while hydroxylation of 25-hydroxyvitamin D3 at position 1alpha by CYP27B1 is an essential step in its activation. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 75-93 26501255-1 2015 Vitamin D3 shows tumoristatic and anticancer effects by acting through the vitamin D receptor (VDR), while hydroxylation of 25-hydroxyvitamin D3 at position 1alpha by CYP27B1 is an essential step in its activation. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 95-98 25741777-1 2015 Vitamin D3 is one of the few natural compounds that has, via its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) and the transcription factor vitamin D receptor (VDR), a direct effect on gene regulation. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 149-167 25835512-3 2015 We conducted a clinical study to determine whether oral cholecalciferol supplementation would exert direct bioactivity in human skin through modulation of the VD receptor (VDR). Cholecalciferol 56-71 vitamin D receptor Homo sapiens 159-170 25835512-3 2015 We conducted a clinical study to determine whether oral cholecalciferol supplementation would exert direct bioactivity in human skin through modulation of the VD receptor (VDR). Cholecalciferol 56-71 vitamin D receptor Homo sapiens 172-175 25827670-0 2015 Effect of vitamin D3 supplementation and influence of BsmI polymorphism of the VDR gene of the inflammatory profile and oxidative stress in elderly women with vitamin D insufficiency: Vitamin D3 megadose reduces inflammatory markers. Cholecalciferol 184-194 vitamin D receptor Homo sapiens 79-82 25741777-1 2015 Vitamin D3 is one of the few natural compounds that has, via its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) and the transcription factor vitamin D receptor (VDR), a direct effect on gene regulation. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 169-172 25639477-2 2015 With metabolic enzymes for vitamin D3 activation and vitamin D receptors (VDR) now identified in a variety of immune cells, the active vitamin D3 metabolite 1,25(OH)2D3, is thought to possess immunomodulatory properties. Cholecalciferol 135-145 vitamin D receptor Homo sapiens 53-72 25639477-2 2015 With metabolic enzymes for vitamin D3 activation and vitamin D receptors (VDR) now identified in a variety of immune cells, the active vitamin D3 metabolite 1,25(OH)2D3, is thought to possess immunomodulatory properties. Cholecalciferol 135-145 vitamin D receptor Homo sapiens 74-77 25875760-2 2015 Using samples from a 5-month vitamin D3 intervention study (VitDmet), we recently reported that the expression of 12 VDR target genes in peripheral blood mononuclear cells (PBMCs) as well as 12 biochemical and clinical parameters of the study participants are significantly triggered by vitamin D3. Cholecalciferol 287-297 vitamin D receptor Homo sapiens 117-120 25875760-1 2015 Vitamin D3 has transcriptome- and genome-wide effects and activates, via the binding of its metabolite 1alpha,25-dihydroxyvitamin D3 to the transcription factor vitamin D receptor (VDR), several hundred target genes. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 161-179 25875760-1 2015 Vitamin D3 has transcriptome- and genome-wide effects and activates, via the binding of its metabolite 1alpha,25-dihydroxyvitamin D3 to the transcription factor vitamin D receptor (VDR), several hundred target genes. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 181-184 25875760-2 2015 Using samples from a 5-month vitamin D3 intervention study (VitDmet), we recently reported that the expression of 12 VDR target genes in peripheral blood mononuclear cells (PBMCs) as well as 12 biochemical and clinical parameters of the study participants are significantly triggered by vitamin D3. Cholecalciferol 29-39 vitamin D receptor Homo sapiens 117-120 24975273-4 2014 Using adipose tissue biopsy samples from 47 participants of a 5-month vitamin D3 intervention study, we demonstrated that all four primary VDR target genes can serve as biomarkers for the vitamin D3 responsiveness of human individuals. Cholecalciferol 70-80 vitamin D receptor Homo sapiens 139-142 25448738-1 2015 Vitamin D3 is a pleiotropic signaling molecule that has via activation of the transcription factor vitamin D receptor (VDR) a direct effect on the expression of more than 100 genes. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 99-117 25448738-1 2015 Vitamin D3 is a pleiotropic signaling molecule that has via activation of the transcription factor vitamin D receptor (VDR) a direct effect on the expression of more than 100 genes. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 119-122 25799416-1 2015 BACKGROUND: Vitamin D3 is a secoster oid that exerts its effect by binding to its nuclear receptor called vitamin D receptor (VDR), inducing apoptosis and thereby inhibiting cell proliferation in cancer cells. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 106-124 25799416-1 2015 BACKGROUND: Vitamin D3 is a secoster oid that exerts its effect by binding to its nuclear receptor called vitamin D receptor (VDR), inducing apoptosis and thereby inhibiting cell proliferation in cancer cells. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 126-129 25070320-0 2014 Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial. Cholecalciferol 68-78 vitamin D receptor Homo sapiens 41-44 25070320-10 2014 The increase in [25(OH)D] due to vitamin D3 supplementation was modified by genotypes at rs10766197 near CYP2R1, rs6013897 near CYP24A1, and rs7968585 near VDR. Cholecalciferol 33-43 vitamin D receptor Homo sapiens 156-159 25070320-11 2014 CONCLUSIONS: The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in vitamin D 25-hydroxylase (CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D receptor (VDR) genes. Cholecalciferol 55-65 vitamin D receptor Homo sapiens 203-221 25070320-11 2014 CONCLUSIONS: The increase in [25(OH)D] attributable to vitamin D3 supplementation may vary according to common genetic differences in vitamin D 25-hydroxylase (CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D receptor (VDR) genes. Cholecalciferol 55-65 vitamin D receptor Homo sapiens 223-226 25479835-0 2015 Effects of 1,25-dihydroxyvitamin D3 and vitamin D3 on the expression of the vitamin d receptor in human skeletal muscle cells. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 76-94 25479835-2 2015 We conducted a series of studies to examine the (1) effect of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on VDR gene expression in human primary myoblasts, (2) effect of 16-week supplementation with vitamin D3 on intramuscular VDR gene expression in older women, and (3) association between serum 25-hydroxyvitamin D (25OHD) and intramuscular VDR protein concentration in older adults. Cholecalciferol 76-86 vitamin D receptor Homo sapiens 104-107 25479835-5 2015 Intramuscular VDR mRNA was significantly different from placebo after 16 weeks of vitamin D3 (1.2+-0.99; -3.2+-1.7, respectively; P=0.04). Cholecalciferol 82-92 vitamin D receptor Homo sapiens 14-17 25479835-9 2015 25OHD is associated with VDR protein and 16 weeks of supplementation with vitamin D3 resulted in a persistent increase in VDR gene expression of vitamin D3 in muscle tissue biopsies. Cholecalciferol 74-84 vitamin D receptor Homo sapiens 122-125 25479835-9 2015 25OHD is associated with VDR protein and 16 weeks of supplementation with vitamin D3 resulted in a persistent increase in VDR gene expression of vitamin D3 in muscle tissue biopsies. Cholecalciferol 145-155 vitamin D receptor Homo sapiens 122-125 25716812-2 2015 To express its biological action, active vitamin D3 (1alpha,25-dihydroxyvitamin D3) interacts with three proteins : vitamin D binding protein (DBP), vitamin D receptor (VDR), and CYP24A1. Cholecalciferol 41-51 vitamin D receptor Homo sapiens 149-167 25716812-2 2015 To express its biological action, active vitamin D3 (1alpha,25-dihydroxyvitamin D3) interacts with three proteins : vitamin D binding protein (DBP), vitamin D receptor (VDR), and CYP24A1. Cholecalciferol 41-51 vitamin D receptor Homo sapiens 169-172 25667505-2 2015 This important medical problem leads to the question, whether an insight into the genome-wide actions of the transcription factor vitamin D receptor (VDR) and its high affinity ligand 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) can help in a more global appreciation of the physiological impact of vitamin D3. Cholecalciferol 203-213 vitamin D receptor Homo sapiens 130-148 25667505-2 2015 This important medical problem leads to the question, whether an insight into the genome-wide actions of the transcription factor vitamin D receptor (VDR) and its high affinity ligand 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) can help in a more global appreciation of the physiological impact of vitamin D3. Cholecalciferol 203-213 vitamin D receptor Homo sapiens 150-153 24975273-4 2014 Using adipose tissue biopsy samples from 47 participants of a 5-month vitamin D3 intervention study, we demonstrated that all four primary VDR target genes can serve as biomarkers for the vitamin D3 responsiveness of human individuals. Cholecalciferol 188-198 vitamin D receptor Homo sapiens 139-142 24975273-7 2014 Using human adipocytes as examples, we show that such ubiquitous VDR target genes can be used as markers for the individual"s response to a supplementation with vitamin D3. Cholecalciferol 161-171 vitamin D receptor Homo sapiens 65-68 24461581-5 2014 RESULTS: Here we show that mouse and human mast cells can convert 25OHD3 to 1alpha,25(OH)2D3 through CYP27B1 activity and that both of these vitamin D3 metabolites suppressed IgE-induced mast cell-derived proinflammatory and vasodilatory mediator production in a VDR-dependent manner in vitro. Cholecalciferol 141-151 vitamin D receptor Homo sapiens 263-266 24854954-0 2014 Primary vitamin D receptor target genes as biomarkers for the vitamin D3 status in the hematopoietic system. Cholecalciferol 62-72 vitamin D receptor Homo sapiens 8-26 24892558-12 2014 VDR- or VEGF blockade reduced tubule formation, partially restorable by vitamin D3. Cholecalciferol 72-82 vitamin D receptor Homo sapiens 0-3 24922634-1 2014 BACKGROUND: Vitamin D3, acting via vitamin D receptor (VDR) affects a wide range of biological activities, including inhibition of proliferation and angiogenesis, with net antitumor effects. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 35-53 24922634-1 2014 BACKGROUND: Vitamin D3, acting via vitamin D receptor (VDR) affects a wide range of biological activities, including inhibition of proliferation and angiogenesis, with net antitumor effects. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 55-58 24597546-9 2014 Upon inhibition of the vitamin D3-metabolizing enzymes (cytochrome P450s), 25(OH)D3 increased ROS production, potentially due to its known (low) affinity for VDR. Cholecalciferol 23-33 vitamin D receptor Homo sapiens 158-161 24108316-0 2013 A randomized study on the effect of vitamin D3 supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. Cholecalciferol 36-46 vitamin D receptor Homo sapiens 97-115 25486939-1 2014 The hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1a), has a wide variety of biological activities and its major molecular target is considered to be the vitamin D receptor (VDR). Cholecalciferol 30-40 vitamin D receptor Homo sapiens 177-195 25486939-1 2014 The hormonally active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1a), has a wide variety of biological activities and its major molecular target is considered to be the vitamin D receptor (VDR). Cholecalciferol 30-40 vitamin D receptor Homo sapiens 197-200 24466411-2 2014 A full vitamin D (refers to vitamin D2 and D3) endocrine system, characterized by a specific VDR (vitamin D receptor, member of the nuclear receptor family), specific vitamin D metabolizing CYP450 enzymes regulated by calciotropic hormones and a dedicated plasma transport-protein is only found in vertebrates. Cholecalciferol 43-45 vitamin D receptor Homo sapiens 93-96 24466411-2 2014 A full vitamin D (refers to vitamin D2 and D3) endocrine system, characterized by a specific VDR (vitamin D receptor, member of the nuclear receptor family), specific vitamin D metabolizing CYP450 enzymes regulated by calciotropic hormones and a dedicated plasma transport-protein is only found in vertebrates. Cholecalciferol 43-45 vitamin D receptor Homo sapiens 98-116 23564710-1 2014 The vitamin D signal transduction system involves a series of cytochrome P450-containing sterol hydroxylases to generate and degrade the active hormone, 1alpha,25-dihydroxyvitamin D3, which serves as a ligand for the vitamin D receptor-mediated transcriptional gene expression described in companion articles in this review series. Cholecalciferol 180-182 vitamin D receptor Homo sapiens 217-235 24918275-3 2014 Nowadays, growing attention is focused on the study of the interactions of the active form of vitamin D3 with its receptor and inhibitory effect of vitamin D3 receptor polymorphisms on multiple signaling pathways involved in proliferative and metastatic processes. Cholecalciferol 94-104 vitamin D receptor Homo sapiens 148-167 24918275-5 2014 It summarizes current knowledge of malignant melanoma in regard to the role of the active form of vitamin D3 binding to vitamin D3 receptor (VDR), as well as it describes the influence of polymorphisms of VDR on the inhibition of HH. Cholecalciferol 98-108 vitamin D receptor Homo sapiens 120-139 24918275-5 2014 It summarizes current knowledge of malignant melanoma in regard to the role of the active form of vitamin D3 binding to vitamin D3 receptor (VDR), as well as it describes the influence of polymorphisms of VDR on the inhibition of HH. Cholecalciferol 98-108 vitamin D receptor Homo sapiens 141-144 24108316-10 2013 CONCLUSION: Vitamin D3 supplementation increased intramyonuclear VDR concentration by 30% and increased muscle fiber size by 10% in older, mobility-limited, vitamin D-insufficient women. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 65-68 23593176-3 2013 Recent studies implicate that hormones including glucocorticoids (ligand for glucocorticoid receptor) and vitamin D3 (ligand for vitamin D receptor) protect or promote repair of podocytes from injury. Cholecalciferol 106-116 vitamin D receptor Homo sapiens 129-147 23853726-1 2013 The hormonally active form of vitamin D3, 1,25(OH)2D3 (calcitriol), exerts actions through VDR receptor, which acts as a transcriptional factor. Cholecalciferol 30-40 vitamin D receptor Homo sapiens 91-94 23485413-6 2013 Interaction analyses showed that VDR FokI genotypes modified the effect of vitamin D3 on changes in the HY stage (P-interaction = 0.045), UPDRS total (P-interaction = 0.039), and UPDRS part II (P-interaction = 0.021). Cholecalciferol 75-85 vitamin D receptor Homo sapiens 33-36 23375797-3 2013 Vitamin D3 is synthesized by the enzyme, CYP27B1, and signals via the nuclear vitamin D3 receptor. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 78-97 23375797-10 2013 Vitamin D3 receptor, CYP24A1 and CYP27B1 expression was measured in cholangiocarcinoma cells stimulated with vehicle or vitamin D3. Cholecalciferol 120-130 vitamin D receptor Homo sapiens 0-19 23375797-12 2013 Vitamin D3 induced nuclear translocation of vitamin D3 receptor in cholangiocarcinoma and decreased cholangiocarcinoma growth. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 44-63 22989379-5 2012 All new vitamin D3 analogues bound less strongly to the VDR than 1alpha,25-dihydroxyvitamin D3 but had similar antiproliferative, pro-differentiating, and transcriptional activity as the native hormone. Cholecalciferol 8-18 vitamin D receptor Homo sapiens 56-59 23489420-5 2013 Based on the induction of a transcriptional activator consisting of the vitamin D receptor fused to the Gal4 DNA-binding domain, the vitamin D3-responsive sensor facilitates non-invasive and rapid assessment of permeability and functional properties of vitamin D3 analogues. Cholecalciferol 133-143 vitamin D receptor Homo sapiens 72-90 23489420-5 2013 Based on the induction of a transcriptional activator consisting of the vitamin D receptor fused to the Gal4 DNA-binding domain, the vitamin D3-responsive sensor facilitates non-invasive and rapid assessment of permeability and functional properties of vitamin D3 analogues. Cholecalciferol 253-263 vitamin D receptor Homo sapiens 72-90 23076256-1 2012 Vitamin D(3) is a neurosteroid that mediates its effects via the vitamin D receptor (VDR). Cholecalciferol 0-12 vitamin D receptor Homo sapiens 65-83 23076256-1 2012 Vitamin D(3) is a neurosteroid that mediates its effects via the vitamin D receptor (VDR). Cholecalciferol 0-12 vitamin D receptor Homo sapiens 85-88 22930071-0 2012 Synthesis of vitamin D3 derivatives with nitrogen-linked substituents at A-ring C-2 and evaluation of their vitamin D receptor-mediated transcriptional activity. Cholecalciferol 13-23 vitamin D receptor Homo sapiens 108-126 22910291-8 2012 The effect of vitamin D3 was mediated by both a nongenomic pathway through MEK/ERK and a genomic pathway involving binding of vitamin D3 receptor to the dysferlin promoter. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 126-145 23097629-9 2012 During NTera2 tumor formation, down-regulation of VDR was observed, resulting in limited responsiveness to cholecalciferol and 1,25(OH)(2)D(3) treatment in vivo. Cholecalciferol 107-122 vitamin D receptor Homo sapiens 50-53 21477267-4 2012 Vitamin D3 exerts its actions through the vitamin D receptor, which is known to be an important regulator of P-glycoprotein (P-gp). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 42-60 20642435-1 2010 Vitamin-D-receptor (VDR) mediates immunomodulatory effects of vitamin-D3 (VD3). Cholecalciferol 62-72 vitamin D receptor Homo sapiens 0-18 21397016-0 2011 A human vitamin D receptor mutant activated by cholecalciferol. Cholecalciferol 47-62 vitamin D receptor Homo sapiens 8-26 21397016-6 2011 Furthermore, via random mutagenesis, a hVDR mutant, H305F/H397Y, was discovered to bind a novel small molecule, cholecalciferol, a precursor in the 1alpha,25-dihydroxyvitamin D(3) biosynthetic pathway, which does not activate wild-type hVDR. Cholecalciferol 112-127 vitamin D receptor Homo sapiens 39-43 21397016-6 2011 Furthermore, via random mutagenesis, a hVDR mutant, H305F/H397Y, was discovered to bind a novel small molecule, cholecalciferol, a precursor in the 1alpha,25-dihydroxyvitamin D(3) biosynthetic pathway, which does not activate wild-type hVDR. Cholecalciferol 112-127 vitamin D receptor Homo sapiens 236-240 21397016-8 2011 In silico docking analysis of the variant displays a dramatic conformational shift of cholecalciferol in the ligand binding pocket in comparison to the docked analysis of cholecalciferol with wild-type hVDR. Cholecalciferol 86-101 vitamin D receptor Homo sapiens 202-206 21397016-8 2011 In silico docking analysis of the variant displays a dramatic conformational shift of cholecalciferol in the ligand binding pocket in comparison to the docked analysis of cholecalciferol with wild-type hVDR. Cholecalciferol 171-186 vitamin D receptor Homo sapiens 202-206 21696575-0 2011 Efficacy of vitamin D3-fortified-yogurt drink on anthropometric, metabolic, inflammatory and oxidative stress biomarkers according to vitamin D receptor gene polymorphisms in type 2 diabetic patients: a study protocol for a randomized controlled clinical trial. Cholecalciferol 12-22 vitamin D receptor Homo sapiens 134-152 21483824-1 2011 BACKGROUND: The 1alpha,25-dihydroxy-3-epi-vitamin-D3 (1alpha,25(OH)2-3-epi-D3), a natural metabolite of the seco-steroid vitamin D3, exerts its biological activity through binding to its cognate vitamin D nuclear receptor (VDR), a ligand dependent transcription regulator. Cholecalciferol 121-131 vitamin D receptor Homo sapiens 195-221 21483824-1 2011 BACKGROUND: The 1alpha,25-dihydroxy-3-epi-vitamin-D3 (1alpha,25(OH)2-3-epi-D3), a natural metabolite of the seco-steroid vitamin D3, exerts its biological activity through binding to its cognate vitamin D nuclear receptor (VDR), a ligand dependent transcription regulator. Cholecalciferol 121-131 vitamin D receptor Homo sapiens 223-226 21395540-3 2011 These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR). Cholecalciferol 43-53 vitamin D receptor Homo sapiens 244-262 21395540-3 2011 These metabolites (oxysterols, bile acids, vitamin D3) act as activators of a battery of nuclear receptors, in particular liver X receptor (LXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR), farnesoid X receptor (FXR) and vitamin D receptor (VDR). Cholecalciferol 43-53 vitamin D receptor Homo sapiens 264-267 21382175-0 2011 The effect of vitamin D3 and ketoconazole combination on VDR-mediated P-gp expression and function in human colon adenocarcinoma cells: implications in drug disposition and resistance. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 57-60 21458526-0 2011 A novel interaction between insulin-like growth factor binding protein-6 and the vitamin D receptor inhibits the role of vitamin D3 in osteoblast differentiation. Cholecalciferol 121-131 vitamin D receptor Homo sapiens 81-99 21084270-8 2011 In patients supplemented with both calcium and vitamin D3, VDR expression increased 19% (P=0.13) and CaR expression increased 24% (P=0.05). Cholecalciferol 47-57 vitamin D receptor Homo sapiens 59-62 22180837-1 2011 Derivatives of vitamin D(3) containing a second side-chain emanating at C-20 are known as gemini and act as vitamin D receptor agonists. Cholecalciferol 15-27 vitamin D receptor Homo sapiens 108-126 21067953-3 2010 Immune cells that produce calcitriol also express the vitamin D receptor (VDR) and the enzymes needed to metabolize vitamin D3 (1alpha-, 25-, and 24-hydroxylases). Cholecalciferol 116-126 vitamin D receptor Homo sapiens 54-72 21067953-3 2010 Immune cells that produce calcitriol also express the vitamin D receptor (VDR) and the enzymes needed to metabolize vitamin D3 (1alpha-, 25-, and 24-hydroxylases). Cholecalciferol 116-126 vitamin D receptor Homo sapiens 74-77 20642435-1 2010 Vitamin-D-receptor (VDR) mediates immunomodulatory effects of vitamin-D3 (VD3). Cholecalciferol 62-72 vitamin D receptor Homo sapiens 20-23 20171278-7 2010 Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription. Cholecalciferol 306-316 vitamin D receptor Homo sapiens 52-55 20171278-7 2010 Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription. Cholecalciferol 306-316 vitamin D receptor Homo sapiens 97-100 20171278-7 2010 Here, we briefly summarize our findings for all the VDR/RXR cis-acting transcriptional elements (VDR/RXR cistrome) in pre-osteoblastic cells, MC3T3-E1, provide a few examples of this dynamic control by VDR and 1,25(OH)2D3, and demonstrate that distal transcriptional control contributes to the majority of vitamin D3-mediated transcription. Cholecalciferol 306-316 vitamin D receptor Homo sapiens 97-100 20007751-3 2010 Cholecalciferol therapy increased serum 25(OH)D levels four-fold, monocyte vitamin D receptor expression three-fold, and 24-hydroxylase expression; therapy decreased monocyte 1alpha-hydroxylase levels. Cholecalciferol 0-15 vitamin D receptor Homo sapiens 75-93 19885846-5 2010 Here, we demonstrate that in osteoblastic cells, the VDR binds to the nuclear matrix in a vitamin D(3)-dependent manner. Cholecalciferol 90-102 vitamin D receptor Homo sapiens 53-56 20089776-6 2010 Endpoint serum PTH was lower (P < 0.05) in the 3 cholecalciferol-supplemented groups compared with that in the placebo group in > or = 64-y olds, but cholecalciferol supplementation did not affect other markers in either cohort and there was no significant interaction with VDR genotype. Cholecalciferol 52-67 vitamin D receptor Homo sapiens 280-283 19660988-1 2009 Paricalcitol (19-nor-1,25/OH(2)/D(2)), a second generation vitamin D receptor (VDR) activator, is a synthetic analogue of vitamin D3. Cholecalciferol 122-132 vitamin D receptor Homo sapiens 59-77 19647104-8 2009 RESULTS: After one year, VDR gene polymorphisms using Bsm1 and TaqI restriction enzymes were associated with percent changes in bone area, BMC and BMD at multiple skeletal sites in the Vitamin D3 group but not in the placebo group. Cholecalciferol 185-195 vitamin D receptor Homo sapiens 25-28 19701245-6 2009 Vitamin D3, an effective chemopreventive agent, interrupted this crosstalk by blocking the constitutive activation of STAT1 and the production of IL-1beta in macrophages, and therefore-in a vitamin D receptor-dependent manner-inhibited the ability of macrophages to activate Wnt signaling in colon carcinoma cells. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 190-208 19660988-1 2009 Paricalcitol (19-nor-1,25/OH(2)/D(2)), a second generation vitamin D receptor (VDR) activator, is a synthetic analogue of vitamin D3. Cholecalciferol 122-132 vitamin D receptor Homo sapiens 79-82 19733911-3 2009 The secondary bile acid lithocholic acid (LCA) is a ligand of the vitamin D receptor (VDR) and can carry out in vivo functions of vitamin D3. Cholecalciferol 130-140 vitamin D receptor Homo sapiens 66-84 19733911-3 2009 The secondary bile acid lithocholic acid (LCA) is a ligand of the vitamin D receptor (VDR) and can carry out in vivo functions of vitamin D3. Cholecalciferol 130-140 vitamin D receptor Homo sapiens 86-89 19244278-2 2009 1,25-Dihydroxyvitamin D3 [1,25(OH)2D3], a potent ligand for the nuclear receptor vitamin D receptor (VDR), has been shown to decrease the risk of osteoporosis, some types of cancer and cardiovascular disease, suggesting an opposing effect of vitamin D3 to cigarette smoking. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 101-104 19517319-1 2009 Elocalcitol, which had been under development by BioXell SpA, is a synthetic derivative of vitamin D3 that regulates cell proliferation and apoptosis via its binding to the vitamin D receptor. Cholecalciferol 91-101 vitamin D receptor Homo sapiens 173-191 18248997-0 2008 The 2alpha-(3-hydroxypropyl) group as an active motif in vitamin D3 analogues as agonists of the mutant vitamin D receptor (Arg274Leu). Cholecalciferol 57-67 vitamin D receptor Homo sapiens 104-122 17707062-1 2007 PURPOSE: The active form of vitamin D3, that is 1alpha,25-dihydroxyvitamin D3, binds with vitamin D receptor, which forms a complex with retinoid X receptors alpha, beta and gamma to manifest antitumor effects. Cholecalciferol 28-38 vitamin D receptor Homo sapiens 90-108 17325131-0 2007 Vitamin D3 derivatives with adamantane or lactone ring side chains are cell type-selective vitamin D receptor modulators. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 91-109 17487855-8 2007 Treatment with 1,25(OH)(2)D(3), an active metabolite of vitamin D3, in the CCA cell lines with high expression of VDR significantly reduced cell proliferation in a dose-dependent manner. Cholecalciferol 56-66 vitamin D receptor Homo sapiens 114-117 16598763-3 2006 THP-1 macrophages and preconfluent CaCo-2 cells contain the vitamin D receptor (VDR), possess 25-hydroxylase (CYP2R1 and CYP27A1) and 1alpha-hydroxylase (CYP27B1) activity, and survive the low UVB doses essential for vitamin D3 photoproduction. Cholecalciferol 217-227 vitamin D receptor Homo sapiens 60-78 16598763-3 2006 THP-1 macrophages and preconfluent CaCo-2 cells contain the vitamin D receptor (VDR), possess 25-hydroxylase (CYP2R1 and CYP27A1) and 1alpha-hydroxylase (CYP27B1) activity, and survive the low UVB doses essential for vitamin D3 photoproduction. Cholecalciferol 217-227 vitamin D receptor Homo sapiens 80-83 16518840-1 2006 Our previous study demonstrate that vitamin D3 induces the binding of vitamin D3 receptor (VDR) to Sp1 transcription factor and stimulates p27Kip1 expression via the Sp1 consensus sequences in the promoter. Cholecalciferol 36-46 vitamin D receptor Homo sapiens 70-89 16518840-1 2006 Our previous study demonstrate that vitamin D3 induces the binding of vitamin D3 receptor (VDR) to Sp1 transcription factor and stimulates p27Kip1 expression via the Sp1 consensus sequences in the promoter. Cholecalciferol 36-46 vitamin D receptor Homo sapiens 91-94 16518840-4 2006 In consistent with our previous results, we found that expression of wild-type VDR in SW620 colon cancer cells, which expressed very low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity and protein expression. Cholecalciferol 172-182 vitamin D receptor Homo sapiens 79-82 16518840-6 2006 DNA affinity precipitation assay (DAPA) showed that both wild-type and deletion mutant of VDR bound to the DNA probe corresponding to the Sp1 binding site in the p27Kip1 promoter in a vitamin D3-dependent manner indicating deletion of AF-2 domain does not affect the interaction between VDR and Sp1. Cholecalciferol 184-194 vitamin D receptor Homo sapiens 90-93 16886688-3 2006 MATERIALS AND METHODS: Vitamin D receptor (VDR)- positive MCF-7 cells in culture were stimulated with the vitamin D metabolites vitamin D3, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 for 24, 48; 72 and 96 hours in physiological and supraphysiological concentrations. Cholecalciferol 128-138 vitamin D receptor Homo sapiens 23-41 16886688-3 2006 MATERIALS AND METHODS: Vitamin D receptor (VDR)- positive MCF-7 cells in culture were stimulated with the vitamin D metabolites vitamin D3, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 for 24, 48; 72 and 96 hours in physiological and supraphysiological concentrations. Cholecalciferol 128-138 vitamin D receptor Homo sapiens 43-46 16690021-6 2006 The data suggest that VDR-mediated inhibition of 25-hydroxylase(s) by vitamin D3 metabolites at the transcriptional level may play an important role in the regulation of 25-hydroxyvitamin D3 production in liver and other tissues. Cholecalciferol 70-80 vitamin D receptor Homo sapiens 22-25 17163485-10 2006 hCAR inhibited hVDR-mediated vitamin D3 induction of hSULT2A1 but not methotrexate induction of hSULT2A1. Cholecalciferol 29-39 vitamin D receptor Homo sapiens 15-19 16651407-6 2006 Among them, we focused on the vitamin D receptor (VDR) gene because vitamin D3 has recently been used for chemoprevention of human tumors. Cholecalciferol 68-78 vitamin D receptor Homo sapiens 30-48 16651407-6 2006 Among them, we focused on the vitamin D receptor (VDR) gene because vitamin D3 has recently been used for chemoprevention of human tumors. Cholecalciferol 68-78 vitamin D receptor Homo sapiens 50-53 16651407-9 2006 In addition, p53 induced VDR target genes in a vitamin D3-dependent manner. Cholecalciferol 47-57 vitamin D receptor Homo sapiens 25-28 16483768-0 2006 Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 45-48 15601870-3 2005 The CCAAT box on the ODF gene is required for its transcriptional induction by vitamin D3, suggesting that NF-Y coregulates this promoter along with VDR. Cholecalciferol 79-89 vitamin D receptor Homo sapiens 149-152 16158969-0 2005 Correlation between VDR expression and antiproliferative activity of vitamin D3 compounds in combination with cytostatics. Cholecalciferol 69-79 vitamin D receptor Homo sapiens 20-23 16158254-6 2005 Results show that cholecalciferol, at physiological levels: (i) inhibits anchorage-dependent growth (ii) induces differentiation by increasing PSA expression and (iii) exerts its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptors (RXRs), and androgen receptor (AR). Cholecalciferol 18-33 vitamin D receptor Homo sapiens 204-222 16158254-6 2005 Results show that cholecalciferol, at physiological levels: (i) inhibits anchorage-dependent growth (ii) induces differentiation by increasing PSA expression and (iii) exerts its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptors (RXRs), and androgen receptor (AR). Cholecalciferol 18-33 vitamin D receptor Homo sapiens 224-227 16158255-4 2005 Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner. Cholecalciferol 0-15 vitamin D receptor Homo sapiens 342-360 16158255-4 2005 Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner. Cholecalciferol 0-15 vitamin D receptor Homo sapiens 362-365 15864137-0 2005 Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Cholecalciferol 113-123 vitamin D receptor Homo sapiens 0-18 16158255-7 2005 Cholecalciferol has effects similar to those of calcitriol on growth, MMP activity, and VDR. Cholecalciferol 0-15 vitamin D receptor Homo sapiens 88-91 15601870-5 2005 Stimulation with vitamin D3 facilitates the recruitment of VDR and p300 onto the ODF promoter, resulting in acetylation of histone H4 in an NF-Y-independent manner. Cholecalciferol 17-27 vitamin D receptor Homo sapiens 59-62 15876428-5 2004 The biologically active form of vitamin D3, 1alpha,25-dihydroxy vitamin D3 [1,25(OH)2D3], induced VDR in THP-1 cells after 24 h treatment, and LPS inhibited 1,25(OH)2D3-mediated VDR induction. Cholecalciferol 32-42 vitamin D receptor Homo sapiens 178-181 15876428-2 2004 Vitamin D receptor (VDR) belongs to a nuclear receptor super-family that mediates the genomic actions of vitamin D3 and regulates gene expression by binding with vitamin D response elements in the promoter region of the cognate gene. Cholecalciferol 105-115 vitamin D receptor Homo sapiens 0-18 15876428-2 2004 Vitamin D receptor (VDR) belongs to a nuclear receptor super-family that mediates the genomic actions of vitamin D3 and regulates gene expression by binding with vitamin D response elements in the promoter region of the cognate gene. Cholecalciferol 105-115 vitamin D receptor Homo sapiens 20-23 15876428-5 2004 The biologically active form of vitamin D3, 1alpha,25-dihydroxy vitamin D3 [1,25(OH)2D3], induced VDR in THP-1 cells after 24 h treatment, and LPS inhibited 1,25(OH)2D3-mediated VDR induction. Cholecalciferol 32-42 vitamin D receptor Homo sapiens 98-101 15368355-2 2004 Vitamin D3 (VD3) exerts its biological actions by binding within cells to VDR. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 74-77 15503649-4 2004 Vitamin D3 exerts its effects through the vitamin D3 receptor (VDR), a ligand-activated nuclear receptor expressed in a wide array of tissue and cell types. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 42-61 15503649-4 2004 Vitamin D3 exerts its effects through the vitamin D3 receptor (VDR), a ligand-activated nuclear receptor expressed in a wide array of tissue and cell types. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 63-66 15225755-0 2004 Model of three-dimensional structure of VDR bound with Vitamin D3 analogs substituted at carbon-2. Cholecalciferol 55-65 vitamin D receptor Homo sapiens 40-43 15064717-0 2004 Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3. Cholecalciferol 87-97 vitamin D receptor Homo sapiens 0-19 15064717-3 2004 In this study, we demonstrated that expression of VDR in SW620 cells, which exhibited low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity. Cholecalciferol 125-135 vitamin D receptor Homo sapiens 50-53 15064717-3 2004 In this study, we demonstrated that expression of VDR in SW620 cells, which exhibited low level of endogenous VDR, increased vitamin D3-stimulated p27Kip1 promoter activity. Cholecalciferol 125-135 vitamin D receptor Homo sapiens 110-113 15064717-7 2004 Collectively, our results suggest that VDR is involved in the induction of p27Kip1 by vitamin D3 and may interact with Sp1 to modulate the expression of target genes that lack VDR response element (VDRE) in their promoters. Cholecalciferol 86-96 vitamin D receptor Homo sapiens 39-42 14696037-2 2004 Studies on the function of the hormonal form of vitamin D3, 1alpha,25-dihydroxyvitamin D3, have been greatly accelerated by the molecular cloning and structural analysis of the vitamin D3 receptor, which is a ligand-activated regulator of gene transcription. Cholecalciferol 48-58 vitamin D receptor Homo sapiens 177-196 14507914-2 2003 In this study, inhibition of RelB expression in DCs exposed to an analog of the active form of vitamin D3 (1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3)) was observed and shown to be mediated by the vitamin D receptor (VDR). Cholecalciferol 95-105 vitamin D receptor Homo sapiens 203-221 14507914-2 2003 In this study, inhibition of RelB expression in DCs exposed to an analog of the active form of vitamin D3 (1alpha,25-dihydroxyvitamin D3 (1alpha,25-(OH)2D3)) was observed and shown to be mediated by the vitamin D receptor (VDR). Cholecalciferol 95-105 vitamin D receptor Homo sapiens 223-226 12400159-0 2002 [Analysis of molecular mechanism of cancer cell differentiation and apoptosis induced by vitamin D3 analogs on the basis of molecular recognition of vitamin D receptor ligand binding domain]. Cholecalciferol 89-99 vitamin D receptor Homo sapiens 149-167 12649563-0 2003 Vitamin D receptor is expressed in pancreatic cancer cells and a vitamin D3 analogue decreases cell number. Cholecalciferol 65-75 vitamin D receptor Homo sapiens 0-18 12893883-3 2003 Here, we show a unique facet of the intermolecular RXR-VDR interaction, in which RXR actively participates in vitamin D3-dependent gene transcription. Cholecalciferol 110-120 vitamin D receptor Homo sapiens 55-58 12893883-7 2003 These results confirm and extend the previous observations suggesting that RXR is a significant contributor to VDR-mediated gene expression and provide a mechanism by which RXR acts as a major contributor to vitamin D3-dependent transcription. Cholecalciferol 208-218 vitamin D receptor Homo sapiens 111-114 12727200-7 2003 We raise a possibility that a conformational change of VDR through its phosphorylation mediated by DNA-PKcs underlies the mechanism of gene repression by 1,25 vitamin D3-bound VDR. Cholecalciferol 159-169 vitamin D receptor Homo sapiens 55-58 12727200-7 2003 We raise a possibility that a conformational change of VDR through its phosphorylation mediated by DNA-PKcs underlies the mechanism of gene repression by 1,25 vitamin D3-bound VDR. Cholecalciferol 159-169 vitamin D receptor Homo sapiens 176-179 12520525-0 2003 Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. Cholecalciferol 121-131 vitamin D receptor Homo sapiens 63-81 12711004-6 2003 TPA pretreatment greatly enhances 1,25-(OH)(2)D(3) stimulated 24-hydroxylase luciferase activity and VDR protein expression, although transactivation is lower in the MCF-7(D(3)Res) cells compared to the parental cell line. Cholecalciferol 46-49 vitamin D receptor Homo sapiens 101-104 12599478-0 2002 Rational design of vitamin D3 analogues which selectively restore activity to a vitamin D receptor mutant associated with rickets. Cholecalciferol 19-29 vitamin D receptor Homo sapiens 80-98 12599478-1 2002 [formula: see text] Vitamin D3-resistant rickets (VDRR) is associated with mutations to the Vitamin D receptor (VDR) which effect ligand-dependent transactivation. Cholecalciferol 20-30 vitamin D receptor Homo sapiens 92-110 12599478-1 2002 [formula: see text] Vitamin D3-resistant rickets (VDRR) is associated with mutations to the Vitamin D receptor (VDR) which effect ligand-dependent transactivation. Cholecalciferol 20-30 vitamin D receptor Homo sapiens 50-53 12174089-11 2002 The lines of evidence for an effect of vitamin D3 in systemic cancer are the laboratory demonstration of relevant effects on cellular growth, differentiation, apoptosis, malignant cell invasion and metastasis; epidemiological findings of an association of the occurrence and outcome of cancers with derangements of vitamin D3/1,25(OH)2D3 and the association of functional polymorphisms of the VDR with the occurrence of certain cancers. Cholecalciferol 39-49 vitamin D receptor Homo sapiens 393-396 11562285-9 2001 The discovery of novel vitamin D3 analogs along with an increased understanding of the biological functions and mechanisms of action of VDR are likely to result in improved treatments for responsive indications. Cholecalciferol 23-33 vitamin D receptor Homo sapiens 136-139 12064463-0 2002 Signaling of monocytic differentiation by a non-hypercalcemic analog of vitamin D3, 1,25(OH)2-5,6 trans-16-ene-vitamin D3, involves nuclear vitamin D receptor (nVDR) and non-nVDR-mediated pathways. Cholecalciferol 72-82 vitamin D receptor Homo sapiens 140-158 12064463-0 2002 Signaling of monocytic differentiation by a non-hypercalcemic analog of vitamin D3, 1,25(OH)2-5,6 trans-16-ene-vitamin D3, involves nuclear vitamin D receptor (nVDR) and non-nVDR-mediated pathways. Cholecalciferol 111-121 vitamin D receptor Homo sapiens 140-158 12362981-2 2002 PRI-1906, an analog of vitamin D2, and PRI-2191, an analog of vitamin D3 bind nuclear vitamin D receptor (nVDR) with substantially lower affinity than 1,25-dihydroxyvitamin D3 (1,25-D3), but have higher differentiation-inducing activity as estimated in HL-60 leukemia cellmodel. Cholecalciferol 62-72 vitamin D receptor Homo sapiens 86-104 10876100-0 2000 An evaluation of the biologic activity and vitamin D receptor binding affinity of the photoisomers of vitamin D3 and previtamin D3. Cholecalciferol 102-112 vitamin D receptor Homo sapiens 43-61 11473365-14 2001 These results indicate that Smad3 coactivates VDR to further enhance TGFbeta signaling and vitamin D3 signaling in the sensitive 184A1 cells. Cholecalciferol 91-101 vitamin D receptor Homo sapiens 46-49 11315990-0 2001 Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements. Cholecalciferol 31-41 vitamin D receptor Homo sapiens 55-74 12903442-8 2000 In addition, EMSA results showed that unliganded VDR and RXR simultaneously bound to the vitamin D3 response element (VDRE) of hsp90 beta gene. Cholecalciferol 89-99 vitamin D receptor Homo sapiens 49-52 10517670-4 1999 In human skin nuclear extracts, VDR exclusively bound to DNA containing vitamin D3 response elements as heterodimers with retinoid X receptors. Cholecalciferol 72-82 vitamin D receptor Homo sapiens 32-35 10343528-1 1999 OBJECTIVES: The active form of vitamin D3, 1 alpha,25 dihydroxyvitamin D3 (1,25D3), through its interaction with vitamin D receptors (VDR), is reported to effect a variety of anabolic and catabolic events, especially in bone and cartilage tissues. Cholecalciferol 31-41 vitamin D receptor Homo sapiens 113-132 10470102-5 1999 1,25(OH)2D3 mediates its biological activities through specific binding to the vitamin D3 receptor (VDR) and subsequent association with vitamin D3 response elements (VDRE) in genes modulated by 1,25(OH)2D3. Cholecalciferol 79-89 vitamin D receptor Homo sapiens 100-103 10330159-0 1999 A two-hit mechanism for vitamin D3-mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAT1 and stabilizes c-Jun. Cholecalciferol 24-34 vitamin D receptor Homo sapiens 133-151 10223184-13 1999 Thus the loss of the growth inhibitory effect of vitamin D3 in HBL100 cells may be caused by the expression of the large T antigen in the cells, and provide further evidence that VDR is required for efficient growth inhibition by vitamin D3. Cholecalciferol 230-240 vitamin D receptor Homo sapiens 179-182 10450176-3 1999 Immunohistochemistry using the specific monoclonal antibody 9A7 gamma directed against the nuclear vitamin D receptor was used to identify receptors for the active metabolite of vitamin D3 (1,25-dihydroxyvitamin D3). Cholecalciferol 178-188 vitamin D receptor Homo sapiens 99-117 10450176-7 1999 CONCLUSIONS: Colorectal cancer tissue expresses the nuclear vitamin D receptor and this could act as a potential therapeutic target for synthetic vitamin D3 differentiating agents. Cholecalciferol 146-156 vitamin D receptor Homo sapiens 60-78 10343528-1 1999 OBJECTIVES: The active form of vitamin D3, 1 alpha,25 dihydroxyvitamin D3 (1,25D3), through its interaction with vitamin D receptors (VDR), is reported to effect a variety of anabolic and catabolic events, especially in bone and cartilage tissues. Cholecalciferol 31-41 vitamin D receptor Homo sapiens 134-137 9209684-2 1997 The actions of 1,25(OH)2D3 are mediated through the intracellular vitamin D receptor (VDR), and the level of VDR is believed to determine the cellular responsiveness to vitamin D3. Cholecalciferol 169-179 vitamin D receptor Homo sapiens 109-112 9602865-2 1998 The effects of vitamin D3 are mediated through the vitamin D3 receptor (VDR). Cholecalciferol 15-25 vitamin D receptor Homo sapiens 51-70 9602865-2 1998 The effects of vitamin D3 are mediated through the vitamin D3 receptor (VDR). Cholecalciferol 15-25 vitamin D receptor Homo sapiens 72-75 9602865-4 1998 In the present study the levels of VDR and RXR in involved and uninvolved psoriatic skin were determined by immunoblotting, and the binding of the VDR-RXR complex to a vitamin D3 response element (VDRE) consisting of two hexanucleotides spaced by three nucleotides (DR-3) by the electrophoretic mobility shift assay. Cholecalciferol 168-178 vitamin D receptor Homo sapiens 147-150 9625456-4 1998 Based on the fact that PTH requires vitamin D3 to take effect on calcium mobilization from bone, it is possible that VDR polymorphism may influence the PTH action on bone. Cholecalciferol 36-46 vitamin D receptor Homo sapiens 117-120 9781285-2 1998 In this paper we show that Cholecalciferol, a poor ligand of the vitamin D receptor, also induces cell death of HU197 human glioblastoma cell line and early passages cultures derived from a recurrent human glioblastoma. Cholecalciferol 27-42 vitamin D receptor Homo sapiens 65-83 9390178-0 1997 Identification of the subdomain in the nuclear receptor for the hormonal form of vitamin D3, 1 alpha,25-dihydroxyvitamin D3, vitamin D receptor, that is covalently modified by an affinity labeling reagent. Cholecalciferol 81-91 vitamin D receptor Homo sapiens 125-143 9390178-1 1997 Multiple physiological actions of the hormonal form of vitamin D3, 1 alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), are mediated by a genomic pathway which is initiated by the highly specific recognition and binding by its cognate receptor (vitamin D receptor, VDR) in the target cells. Cholecalciferol 55-65 vitamin D receptor Homo sapiens 238-256 9390178-1 1997 Multiple physiological actions of the hormonal form of vitamin D3, 1 alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), are mediated by a genomic pathway which is initiated by the highly specific recognition and binding by its cognate receptor (vitamin D receptor, VDR) in the target cells. Cholecalciferol 55-65 vitamin D receptor Homo sapiens 258-261 9344190-5 1997 RESULTS: The vitamin D receptor has been detected in most skin cells, which means that keratinization, hair growth, melanogenesis, fibrogenesis, angiogenesis, and immune-mediated processes are potential targets for vitamin D3. Cholecalciferol 215-225 vitamin D receptor Homo sapiens 13-31 11056661-1 1999 INTRODUCTION: 1alpha,25-dihydroxyvitamin D(3)[1alpha,25(OH)(2)D(3)], the biologically active metabolite of vitamin D3, acts through an intracellular vitamin D receptor (VDR) and has several immunostimulatory effects. Cholecalciferol 107-117 vitamin D receptor Homo sapiens 149-167 11056661-1 1999 INTRODUCTION: 1alpha,25-dihydroxyvitamin D(3)[1alpha,25(OH)(2)D(3)], the biologically active metabolite of vitamin D3, acts through an intracellular vitamin D receptor (VDR) and has several immunostimulatory effects. Cholecalciferol 107-117 vitamin D receptor Homo sapiens 169-172 9258754-2 1997 In this study, we examined the effect of vitamin D3 supplementation on BMD at the femoral neck in relation to VDR genotype. Cholecalciferol 41-51 vitamin D receptor Homo sapiens 110-113 8877104-0 1996 Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 101-120 8940196-2 1996 We reported previously that the induced differentiation of the myelomonocytic cell line U937 by vitamin D3 is facilitated by the transcriptional induction of the p21(WAF1/CIP1) gene by the vitamin D3 receptor (Liu, M., Lee, M.-H., Cohen, M., and Freedman, L. P. (1996) Genes Dev. Cholecalciferol 96-106 vitamin D receptor Homo sapiens 189-208 9176036-2 1997 The active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3, controls calcium absorption in the human duodenum, an effect that is mediated by mucosal vitamin D receptor expression. Cholecalciferol 25-35 vitamin D receptor Homo sapiens 152-170 8841046-1 1996 In order to assess the effect of vitamin D receptor (VDR) gene polymorphisms on vitamin D3 therapy for postmenopausal bone loss. Cholecalciferol 80-90 vitamin D receptor Homo sapiens 33-51 8841046-1 1996 In order to assess the effect of vitamin D receptor (VDR) gene polymorphisms on vitamin D3 therapy for postmenopausal bone loss. Cholecalciferol 80-90 vitamin D receptor Homo sapiens 53-56 8687373-1 1996 The biologically active metabolite of vitamin D (cholecalciferol), i.e. 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], is a secosteroid hormone whose mode of action involves stereospecific interaction with an intracellular receptor protein (vitamin D receptor; VDR). Cholecalciferol 49-64 vitamin D receptor Homo sapiens 234-252 8687373-1 1996 The biologically active metabolite of vitamin D (cholecalciferol), i.e. 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], is a secosteroid hormone whose mode of action involves stereospecific interaction with an intracellular receptor protein (vitamin D receptor; VDR). Cholecalciferol 49-64 vitamin D receptor Homo sapiens 254-257 8028822-2 1994 Evaluation of the gene coding for the vitamin D receptor (VDR) for the hormonally active form of vitamin D3, 1 alpha, 25(OH)2-vitamin D3, indicates the presence of two allelic variants. Cholecalciferol 97-107 vitamin D receptor Homo sapiens 38-56 7606167-1 1995 During the course of our studies to probe the vitamin D ligand-binding domains of vitamin D-binding protein and vitamin D receptor, we developed a synthetic procedure to modify the 3 beta-hydroxyl group of vitamin D3 and its 25-hydroxy- and 1,25-dihydroxy metabolites with a 3"-aminopropylether group. Cholecalciferol 206-216 vitamin D receptor Homo sapiens 112-130 7700077-1 1995 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] mediates its biological activities through specific binding to the vitamin D3 receptor (VDR) and subsequent association with vitamin D3 responsive elements (VDRE) in genes modulated by 1,25(OH)2D3. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 106-125 7700077-1 1995 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] mediates its biological activities through specific binding to the vitamin D3 receptor (VDR) and subsequent association with vitamin D3 responsive elements (VDRE) in genes modulated by 1,25(OH)2D3. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 127-130 7700077-10 1995 In contrast, biologically active vitamin D3 compounds (Cmpds HM, C, V) in a dose-dependent fashion enhanced the VDR/RXR (retinoid X receptor)-VDRE retarded band. Cholecalciferol 33-43 vitamin D receptor Homo sapiens 112-115 9627688-2 1996 The vitamin D receptor (VDR) mediates most, if not all, the effects of vitamin D3. Cholecalciferol 71-81 vitamin D receptor Homo sapiens 4-22 9627688-2 1996 The vitamin D receptor (VDR) mediates most, if not all, the effects of vitamin D3. Cholecalciferol 71-81 vitamin D receptor Homo sapiens 24-27 9627692-3 1996 Because 9-cis-retinoic acid receptors (RXRs) form heterodimers both with RARs and the vitamin D3 receptor (VDR), it is plausible that vitamin D3 may affect retinol metabolism if altered transcription is involved in the regulation of vitamin A-metabolizing enzymes. Cholecalciferol 86-96 vitamin D receptor Homo sapiens 107-110 8622645-7 1996 Conversely, when VDR is overexpressed, vitamin D3 attenuates 9-cis RA induction from an RXR-responsive element. Cholecalciferol 39-49 vitamin D receptor Homo sapiens 17-20 7489414-3 1995 Active vitamin D3 acts via its receptor (VDR), and binding of the ligand-receptor complex to specific promoter regions of the PTH gene inhibits transcription. Cholecalciferol 7-17 vitamin D receptor Homo sapiens 41-44 7489414-4 1995 Active vitamin D3 constitutes a principal regulator of parathyroid cell growth, and polymorphism in the VDR gene has recently been related to bone mineral density and suggested as predisposing to osteoporosis. Cholecalciferol 7-17 vitamin D receptor Homo sapiens 104-107 7565732-3 1995 We therefore examined vitamin D3-mediated repression of activated IL-2 expression by cotransfecting Jurkat cells with IL-2 promoter/reporter constructs and a VDR overexpression vector and by DNA binding. Cholecalciferol 22-32 vitamin D receptor Homo sapiens 158-161 8028822-2 1994 Evaluation of the gene coding for the vitamin D receptor (VDR) for the hormonally active form of vitamin D3, 1 alpha, 25(OH)2-vitamin D3, indicates the presence of two allelic variants. Cholecalciferol 97-107 vitamin D receptor Homo sapiens 58-61 8483269-4 1993 The complex of VDR and 1 alpha,25(OH)2D3 binds to vitamin D3-responsive elements (VDRE) present in the promoter region of target genes of 1 alpha,25(OH)2D3. Cholecalciferol 50-60 vitamin D receptor Homo sapiens 15-30 8393784-6 1993 Accordingly, we show that PMLRAR can both prevent the binding of the vitamin D3 receptor (VDR) to a target sequence in vitro and inhibit vitamin D3-dependent activation of a VDR-responsive reporter gene in transfected cells. Cholecalciferol 69-79 vitamin D receptor Homo sapiens 90-93 1656244-5 1991 Nuclear extracts from cells infected with the hVDR-expressing adenoviruses contain an activity that specifically binds an oligonucleotide with sequences from the rat osteocalcin vitamin D3 response element, as determined by gel mobility shift. Cholecalciferol 178-188 vitamin D receptor Homo sapiens 46-50 35364123-13 2022 GENERAL SIGNIFICANCE: Vitamin D3 supplementation counteracts diabetes-induced kidney damage, most likely through VDR-mediated inhibition of NF-kappaB activation. Cholecalciferol 22-32 vitamin D receptor Homo sapiens 113-116 34867333-8 2021 These findings expand the potential uses of vitamin D3 against CRC and introduce VDR signaling via the enzyme NAT2 as a potential diagnostic and therapeutic target for CRC. Cholecalciferol 44-54 vitamin D receptor Homo sapiens 81-84 34502192-7 2021 Vitamin D3 was identified as responsible for the vitamin D receptor loss, for the increase in neutral sphingomyelinase content and sphingomyelin changes. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 49-67 34757179-0 2022 Vitamin D3 protects against nitrogen mustard-induced apoptosis of the bronchial epithelial cells via activating the VDR/Nrf2/Sirt3 pathway. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 116-119 34757179-10 2022 In conclusion, impaired VDR/Nrf2/Sirt3 axis contributed to NM-induced apoptosis, while vitamin D3 supplementation provides protective effects via the activation of VDR and the improvement of mitochondrial functions. Cholecalciferol 87-97 vitamin D receptor Homo sapiens 164-167 34959778-1 2021 Several recent studies have demonstrated that the direct precursor of vitamin D3, the calcifediol (25(OH)D3), through the binding to the nuclear vitamin D receptor (VDR), is able to regulate the expression of many genes involved in several cellular processes. Cholecalciferol 70-80 vitamin D receptor Homo sapiens 145-163 34959778-1 2021 Several recent studies have demonstrated that the direct precursor of vitamin D3, the calcifediol (25(OH)D3), through the binding to the nuclear vitamin D receptor (VDR), is able to regulate the expression of many genes involved in several cellular processes. Cholecalciferol 70-80 vitamin D receptor Homo sapiens 165-168 34836354-1 2021 Vitamin D3 is an essential micronutrient mediating pleiotropic effects in multiple tissues and cell types via its metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), which activates the transcription factor vitamin D receptor. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 211-229 34206371-0 2021 Knocking out the Vitamin D Receptor Enhances Malignancy and Decreases Responsiveness to Vitamin D3 Hydroxyderivatives in Human Melanoma Cells. Cholecalciferol 88-98 vitamin D receptor Homo sapiens 17-35 35053549-1 2022 The active forms of vitamin D3 (calcitriol and tacalcitol) coupled to the vitamin D receptor (VDR) are known to exhibit anti-cancer properties. Cholecalciferol 20-30 vitamin D receptor Homo sapiens 74-92 35560516-2 2022 Vitamin D3 (VD3 ) through its receptor (VDR) plays an important immunomodulatory role in autoimmune misbalance, being capable of modulating immune responses. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 40-43 35445563-4 2022 We consider the likely biological determinants of cancer outcome, the reported effects of vitamin D3 on these in both cancerous and non-cancerous settings, and how the effect of vitamin D3 might change depending on the integrity of tumour vitamin D receptor (VDR) signalling. Cholecalciferol 178-188 vitamin D receptor Homo sapiens 239-257 35445563-6 2022 In animal models, having defective VDR signalling, vitamin D3 administration decreased survival and increased metastases. Cholecalciferol 51-61 vitamin D receptor Homo sapiens 35-38 35053278-1 2022 1alpha,25-Dihydroxyvitamin D3 (1alpha,25(OH)2D3, 1) is an active form of vitamin D3 and regulates various biological phenomena, including calcium and phosphate homeostasis, bone metabolism, and immune response via binding to and activation of vitamin D receptor (VDR). Cholecalciferol 73-83 vitamin D receptor Homo sapiens 263-266 35126351-5 2021 Cells were stimulated or not with 100 ng/ml tumor necrosis factor alpha (TNF-alpha) or/and 1 nM or/and 0.01 nM vitamin D3 for 72 h. The expression levels of NLRP1, NLRP3, TLR1, TLR2, TLR4, and VDR in all examined SFs were analyzed by quantitative real-time PCR (RT-qPCR). Cholecalciferol 111-121 vitamin D receptor Homo sapiens 193-196 35053278-1 2022 1alpha,25-Dihydroxyvitamin D3 (1alpha,25(OH)2D3, 1) is an active form of vitamin D3 and regulates various biological phenomena, including calcium and phosphate homeostasis, bone metabolism, and immune response via binding to and activation of vitamin D receptor (VDR). Cholecalciferol 73-83 vitamin D receptor Homo sapiens 243-261 35053549-1 2022 The active forms of vitamin D3 (calcitriol and tacalcitol) coupled to the vitamin D receptor (VDR) are known to exhibit anti-cancer properties. Cholecalciferol 20-30 vitamin D receptor Homo sapiens 94-97 33753848-1 2021 The transcription factor vitamin D receptor (VDR) is the high affinity nuclear target of the biologically active form of vitamin D3 (1,25(OH)2D3). Cholecalciferol 121-131 vitamin D receptor Homo sapiens 25-43 3001619-3 1985 vitamin D3-drops for 18 days) of vitamin D-deficiency rickets (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 63-66 2550427-7 1989 This apparent reduction in the affinity of VDR for 1,25-(OH)2D3 was due to degradation of free 1,25-(OH)2[3H]D3 which occurred during whole cell saturation assay. Cholecalciferol 61-63 vitamin D receptor Homo sapiens 43-46 6291527-0 1982 23-keto-25-hydroxyvitamin D3 and 23-keto-1,25-dihydroxyvitamin D3: two new vitamin D3 metabolites with high affinity for the 1,25-dihydroxyvitamin D3 receptor. Cholecalciferol 18-28 vitamin D receptor Homo sapiens 125-158 34032540-0 2022 Vitamin D Receptor (VDR) Allelic Variants Correlating with Response to Vitamin D3 Supplementation in Breast Cancer Survivors. Cholecalciferol 71-81 vitamin D receptor Homo sapiens 0-18 34032540-0 2022 Vitamin D Receptor (VDR) Allelic Variants Correlating with Response to Vitamin D3 Supplementation in Breast Cancer Survivors. Cholecalciferol 71-81 vitamin D receptor Homo sapiens 20-23 34032540-1 2022 We investigated how vitamin D receptor (VDR) allelic variants affect breast cancer survivors" responses to vitamin D3 supplementation to increase circulating 25-hydroxy vitamin D (25(OH)D) levels. Cholecalciferol 107-117 vitamin D receptor Homo sapiens 20-38 34032540-4 2022 The TaqI and BsmI VDR sequence variants modified the effect of vitamin D3 treatment on the plasma 25(OH)D changes (P value = 0.008 for TaqI and P value = 0.0005 for BsmI). Cholecalciferol 63-73 vitamin D receptor Homo sapiens 18-21 34032540-7 2022 VDR allelic variants modulate vitamin D3 supplementation to increase plasma 25(OH) levels in breast cancer survivors. Cholecalciferol 30-40 vitamin D receptor Homo sapiens 0-3 33753848-1 2021 The transcription factor vitamin D receptor (VDR) is the high affinity nuclear target of the biologically active form of vitamin D3 (1,25(OH)2D3). Cholecalciferol 121-131 vitamin D receptor Homo sapiens 45-48 33126474-6 2020 We demonstrated that 1alpha,25(OH)2 vitamin D3 acts via vitamin D receptor in GL15 cells and via neutral sphingomyelinase1, with an enrichment of ceramide pool, in U251 and LN18 cells. Cholecalciferol 36-46 vitamin D receptor Homo sapiens 56-74 32474936-11 2021 Standard PgLPS and Pam3CSK4 increased VDR expression in the presence of vitamin D3 . Cholecalciferol 72-82 vitamin D receptor Homo sapiens 38-41 32474936-13 2021 CONCLUSIONS: This study indicates that the transcriptional activity of VDR is diminished under inflammatory conditions, which might mitigate the effectiveness of vitamin D3 supplementation during periodontal treatment. Cholecalciferol 162-172 vitamin D receptor Homo sapiens 71-74 33288743-1 2020 The bioactive vitamin D3, 1alpha,25(OH)2D3, plays a central role in calcium homeostasis by controlling the activity of the vitamin D receptor (VDR) in various tissues. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 123-141 33288743-1 2020 The bioactive vitamin D3, 1alpha,25(OH)2D3, plays a central role in calcium homeostasis by controlling the activity of the vitamin D receptor (VDR) in various tissues. Cholecalciferol 14-24 vitamin D receptor Homo sapiens 143-146 32829183-1 2020 Vitamin D3 is the precursor of the steroid hormone calcitriol (1alpha,25-dihydroxyvitamin D3), a potent agonist of the transcription factor vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 140-158 32829183-1 2020 Vitamin D3 is the precursor of the steroid hormone calcitriol (1alpha,25-dihydroxyvitamin D3), a potent agonist of the transcription factor vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 160-163 33194806-0 2020 Vitamin D3 Inhibits Helicobacter pylori Infection by Activating the VitD3/VDR-CAMP Pathway in Mice. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 74-77 32542627-3 2020 In addition 65 patients receiving either cholecalciferol or placebo were analyzed during 6 months intervention and 6 months follow-up.T2D risk alleles are VDR rs7975232 "G" (pc=0.031), rs1544410 "G" (pc=0.027) and CYP2R1 rs10741657 "A" (pc=0.016). Cholecalciferol 41-56 vitamin D receptor Homo sapiens 155-158 32740169-3 2020 Linear regression was used to analyze whether the effect of vitamin D3 supplementation on response variables was associated with the selected VDR single nucleotide polymorphisms executing by "association" function in the R package "SNPassoc". Cholecalciferol 60-70 vitamin D receptor Homo sapiens 142-145 32663289-7 2020 We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs). Cholecalciferol 34-49 vitamin D receptor Homo sapiens 163-182 32663289-7 2020 We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs). Cholecalciferol 34-49 vitamin D receptor Homo sapiens 184-187 32663289-7 2020 We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs). Cholecalciferol 51-61 vitamin D receptor Homo sapiens 163-182 32663289-7 2020 We also found that treatment with cholecalciferol (vitamin D3) mitigates MCP-1 induction, likely because of competition between retinoic acid receptors (RARs) and vitamin D receptors (VDR) for their common binding partner retinoid nuclear receptors (RXRs). Cholecalciferol 51-61 vitamin D receptor Homo sapiens 184-187 31387633-12 2019 Upon stimulation with vitamin D3, nuclear translocation of vitamin D receptor (VDR) was observed. Cholecalciferol 22-32 vitamin D receptor Homo sapiens 59-77 32918226-2 2020 The active form of vitamin D, vitamin D3 or calcitriol, binds to the ligand-activated transcription factor vitamin D receptor (VDR) for genomic and non-genomic effects. Cholecalciferol 30-40 vitamin D receptor Homo sapiens 107-125 32918226-2 2020 The active form of vitamin D, vitamin D3 or calcitriol, binds to the ligand-activated transcription factor vitamin D receptor (VDR) for genomic and non-genomic effects. Cholecalciferol 30-40 vitamin D receptor Homo sapiens 127-130 32877827-1 2020 Vitamin D3 is a fat-soluble essential nutrient that affects multiple biologic functions in the organism through calcitriol and the vitamin D3 receptor. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 131-150 32877827-3 2020 The mechanisms of vitamin D3 action involve, among others, polymorphism of vitamin D3 receptor, cell cycle, caspases, and cancer stem cells. Cholecalciferol 18-28 vitamin D receptor Homo sapiens 75-94 31618573-1 2019 Vitamin D3 metabolites are capable of controlling gene expression in mammalian cells through two independent pathways: vitamin D receptor (VDR) and sterol regulatory element-binding protein (SREBP) pathways. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 119-137 31618573-1 2019 Vitamin D3 metabolites are capable of controlling gene expression in mammalian cells through two independent pathways: vitamin D receptor (VDR) and sterol regulatory element-binding protein (SREBP) pathways. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 139-142 31822280-1 2019 BACKGROUND: The deficiency of vitamin D receptor (VDR) or its ligand, vitamin D3, is linked to the development of renal diseases. Cholecalciferol 70-80 vitamin D receptor Homo sapiens 30-48 31822280-1 2019 BACKGROUND: The deficiency of vitamin D receptor (VDR) or its ligand, vitamin D3, is linked to the development of renal diseases. Cholecalciferol 70-80 vitamin D receptor Homo sapiens 50-53 31521173-0 2019 Correction to: Vitamin D receptor gene polymorphisms affecting changes in visceral fat, waist circumference and lipid profile in breast cancer survivors supplemented with vitamin D3. Cholecalciferol 171-181 vitamin D receptor Homo sapiens 15-33 31395070-0 2019 Vitamin D receptor gene polymorphisms affecting changes in visceral fat, waist circumference and lipid profile in breast cancer survivors supplemented with vitamin D3. Cholecalciferol 156-166 vitamin D receptor Homo sapiens 0-18 31395070-5 2019 Multivariate multiple linear regression analyses were used to determine the association between the VDR single-nucleotide polymorphisms (SNPs) and changes in metabolic and anthropometric measures in response to vitamin D3 supplementation. Cholecalciferol 211-221 vitamin D receptor Homo sapiens 100-103 31395070-8 2019 In addition, the heterozygous genotype (Bb) of the BsmI VDR was associated with higher increase in WC following vitamin D3 supplementation, compared to BB [2.7(0.1,5.3)]. Cholecalciferol 112-122 vitamin D receptor Homo sapiens 56-59 31395070-10 2019 CONCLUSIONS: Findings of this study showed that genetic variation in the VDR gene was associated with changes in cardio-metabolic parameters in breast cancer survivors, supplemented with vitamin D3, results could provide a novel insight into better understanding of which subset of individuals benefit most from normalization of vitamin D status. Cholecalciferol 187-197 vitamin D receptor Homo sapiens 73-76 32234325-7 2020 Vitamin D3 restores the autophagic flux inhibited by IAV by upregulating the expression of Syntaxin-17 (STX17) and V-type proton ATPase subunit (ATP6V0A2) thereby causing a concomitant decrease in cellular apoptosis via a Vitamin D3 receptor (VDR) dependent mechanism. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 222-241 32234325-7 2020 Vitamin D3 restores the autophagic flux inhibited by IAV by upregulating the expression of Syntaxin-17 (STX17) and V-type proton ATPase subunit (ATP6V0A2) thereby causing a concomitant decrease in cellular apoptosis via a Vitamin D3 receptor (VDR) dependent mechanism. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 243-246 32375246-3 2020 Restriction Fragment Length Polymorphism was completed for the detection of vitamin D receptor (VDR) gene polymorphism; Results: Serum 25-hydroxy vitamin D3 (vitamin D) levels were found to be 1.6 times elevated in severe dengue cases as compared to healthy controls. Cholecalciferol 76-85 vitamin D receptor Homo sapiens 96-99 32325790-1 2020 The biologically active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), modulates innate and adaptive immunity via genes regulated by the transcription factor vitamin D receptor (VDR). Cholecalciferol 32-42 vitamin D receptor Homo sapiens 176-194 32325790-1 2020 The biologically active form of vitamin D3, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), modulates innate and adaptive immunity via genes regulated by the transcription factor vitamin D receptor (VDR). Cholecalciferol 32-42 vitamin D receptor Homo sapiens 196-199 31769776-0 2019 Synthesis and vitamin D receptor affinity of 16-oxa vitamin D3 analogues. Cholecalciferol 45-62 vitamin D receptor Homo sapiens 14-32 31618573-2 2019 In the present study, we dissect the complex biological activity of vitamin D by designing synthetic vitamin D3 analogs specific for VDR or SREBP pathway, i.e., a VDR activator that lacks SREBP inhibitory activity, or an SREBP inhibitor devoid of VDR activity. Cholecalciferol 101-111 vitamin D receptor Homo sapiens 133-136 31618573-2 2019 In the present study, we dissect the complex biological activity of vitamin D by designing synthetic vitamin D3 analogs specific for VDR or SREBP pathway, i.e., a VDR activator that lacks SREBP inhibitory activity, or an SREBP inhibitor devoid of VDR activity. Cholecalciferol 101-111 vitamin D receptor Homo sapiens 163-166 31618573-2 2019 In the present study, we dissect the complex biological activity of vitamin D by designing synthetic vitamin D3 analogs specific for VDR or SREBP pathway, i.e., a VDR activator that lacks SREBP inhibitory activity, or an SREBP inhibitor devoid of VDR activity. Cholecalciferol 101-111 vitamin D receptor Homo sapiens 163-166 31326626-2 2019 Calcitriol (1,25D3), the most active form of vitamin D3, acts mainly through the vitamin D receptor, regulating the expression of target genes. Cholecalciferol 45-55 vitamin D receptor Homo sapiens 81-99 31352041-4 2019 In the current study, human osteosarcoma Saos-2 cells and primary human osteoblasts were found to express mRNA for the vitamin D receptor as well as activating and deactivating enzymes in vitamin D3 metabolism. Cholecalciferol 188-198 vitamin D receptor Homo sapiens 119-137 31572402-1 2019 The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) activates at sub-nanomolar concentrations the transcription factor vitamin D receptor (VDR). Cholecalciferol 4-14 vitamin D receptor Homo sapiens 137-155 31572402-1 2019 The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) activates at sub-nanomolar concentrations the transcription factor vitamin D receptor (VDR). Cholecalciferol 4-14 vitamin D receptor Homo sapiens 157-160 30916559-2 2019 Vitamin D3 acts via its metabolite 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] as potent agonist of the transcription factor vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 125-143 30916559-2 2019 Vitamin D3 acts via its metabolite 1alpha,25-dihydroxyvitamin D3 [1,25(OH)2D3] as potent agonist of the transcription factor vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 145-148 31043390-1 2019 PURPOSE: The biologically active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (vit D), has immunoregulatory properties via binding vitamin D receptor (VDR). Cholecalciferol 47-57 vitamin D receptor Homo sapiens 137-155 31043390-1 2019 PURPOSE: The biologically active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 (vit D), has immunoregulatory properties via binding vitamin D receptor (VDR). Cholecalciferol 47-57 vitamin D receptor Homo sapiens 157-160 31387633-12 2019 Upon stimulation with vitamin D3, nuclear translocation of vitamin D receptor (VDR) was observed. Cholecalciferol 22-32 vitamin D receptor Homo sapiens 79-82 30478352-10 2019 Treatment of UF cells with Vitamin D3 (100 nM) significantly decreased DNA damage and restored DDR concomitant with VDR induction. Cholecalciferol 27-37 vitamin D receptor Homo sapiens 116-119 31287793-2 2019 miR-99b-3p, the tumor suppressor gene, is not only decreased in GC tissues, but is also induced by vitamin D3 through the vitamin D receptor (VDR) binding on the promoter domain of miR-99b. Cholecalciferol 99-109 vitamin D receptor Homo sapiens 122-140 31287793-2 2019 miR-99b-3p, the tumor suppressor gene, is not only decreased in GC tissues, but is also induced by vitamin D3 through the vitamin D receptor (VDR) binding on the promoter domain of miR-99b. Cholecalciferol 99-109 vitamin D receptor Homo sapiens 142-145 30478352-11 2019 Notably, the PCR array demonstrated that among 75 downregulated genes after VDR KD, 67 (89.3%) were upregulated after vitamin D3 treatment. Cholecalciferol 118-128 vitamin D receptor Homo sapiens 76-79 31092845-1 2019 Vitamin D3 (vitD3) and its active metabolite, calcitriol (1,25-(OH)2D3), affect multiple tissue types by interacting with the vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 126-144 31350967-0 2019 Genetic Variations in VDR could Modulate the Efficacy of Vitamin D3 Supplementation on Inflammatory Markers and Total Antioxidant Capacity among Breast Cancer Women: A Randomized Double Blind Controlled Trial. Cholecalciferol 57-67 vitamin D receptor Homo sapiens 22-25 31350967-4 2019 This study was aimed to assess the impact of vitamin D3 supplementation onthe serum concentration of inflammatory markers and antioxidant capacity with regard to VDR polymorphism in theVDR gene in breast cancer women. Cholecalciferol 45-55 vitamin D receptor Homo sapiens 162-165 31167402-0 2019 Vitamin D Receptor Genetic Variation and Cancer Biomarkers among Breast Cancer Patients Supplemented with Vitamin D3: A Single-Arm Non-Randomized Before and After Trial. Cholecalciferol 106-116 vitamin D receptor Homo sapiens 0-18 31167402-8 2019 Overall, our findings suggest that changes in certain inflammatory biomarkers in breast cancer survivors with low plasma 25(OH)D levels, supplemented with vitamin D3, may depend on VDR SNPs and haplotypes. Cholecalciferol 155-165 vitamin D receptor Homo sapiens 181-184 31092845-1 2019 Vitamin D3 (vitD3) and its active metabolite, calcitriol (1,25-(OH)2D3), affect multiple tissue types by interacting with the vitamin D receptor (VDR). Cholecalciferol 0-10 vitamin D receptor Homo sapiens 146-149 30890957-1 2019 The molecular basis of vitamin D signaling implies that the metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) of the secosteroid vitamin D3 activates the transcription factor vitamin D receptor (VDR), which in turn modulates the expression of hundreds of primary vitamin D target genes. Cholecalciferol 90-100 vitamin D receptor Homo sapiens 180-198 31086078-6 2019 Using the CRISPR-Cas9 editing technology to knockout the vitamin D receptor, we found that the antiviral activity of vitamin D3 and 25(OH)D3 was not impaired in the vitamin D receptor knockout cells. Cholecalciferol 117-127 vitamin D receptor Homo sapiens 57-75 31086078-9 2019 Taken together, this study proposes a novel mode of action for the anti-hepatitis C virus activity of vitamin D3 that is mediated by 25(OH)D3 in a vitamin D receptor-independent mechanism. Cholecalciferol 102-112 vitamin D receptor Homo sapiens 147-165 30972950-0 2019 Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 72-75 30961641-1 2019 OBJECTIVE: Vitamin D receptor (VDR) activities have been noted for a number of B cell malignancies which showed varying sensitivities to vitamin D3 (1,25-dihydroxyvitamin D3, VD3, calcitriol) and its synthetic analogs. Cholecalciferol 137-147 vitamin D receptor Homo sapiens 11-29 30961641-1 2019 OBJECTIVE: Vitamin D receptor (VDR) activities have been noted for a number of B cell malignancies which showed varying sensitivities to vitamin D3 (1,25-dihydroxyvitamin D3, VD3, calcitriol) and its synthetic analogs. Cholecalciferol 137-147 vitamin D receptor Homo sapiens 31-34 30901909-2 2019 Vitamin D3 represents a master example of nutrigenomics, since via its metabolite 1alpha,25-dihydroxyvitamin D3, which binds with high-affinity to the vitamin D receptor, the secosteroid directly affects the epigenome and transcriptome at thousands of loci within the human genome. Cholecalciferol 0-10 vitamin D receptor Homo sapiens 151-169 30890957-1 2019 The molecular basis of vitamin D signaling implies that the metabolite 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) of the secosteroid vitamin D3 activates the transcription factor vitamin D receptor (VDR), which in turn modulates the expression of hundreds of primary vitamin D target genes. Cholecalciferol 90-100 vitamin D receptor Homo sapiens 200-203 31298160-2 2019 The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 acts as a nuclear hormone activating the transcription factor vitamin D receptor (VDR). Cholecalciferol 4-14 vitamin D receptor Homo sapiens 118-136 30967742-5 2019 VDDR2A is a rare autosomal recessive disorder caused by mutation in the Vitamin D receptor gene, leading to end-organ resistance to 1,25(OH)2 Vitamin D3. Cholecalciferol 142-152 vitamin D receptor Homo sapiens 72-90 31298160-2 2019 The vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 acts as a nuclear hormone activating the transcription factor vitamin D receptor (VDR). Cholecalciferol 4-14 vitamin D receptor Homo sapiens 138-141 30568875-1 2019 Objective: Through its receptor (VDR), vitamin D3 plays an important role in a wide variety of cellular processes. Cholecalciferol 39-49 vitamin D receptor Homo sapiens 33-36